Literature DB >> 33959239

NR4A3 (NOR-1) Immunostaining Shows Better Performance than DOG1 Immunostaining in Acinic Cell Carcinoma of Salivary Gland: a Preliminary Study.

Adepitan Owosho1, Donald Tyler2, Olufunlola Adesina3, Oluwole Odujoko4, Kurt Summersgill5.   

Abstract

OBJECTIVES: Acinic cell carcinoma of salivary gland harbours recurrent and specific chromosomal rearrangement [t(4;9)(q13;q31)], resulting in the translocation of secretory calcium-binding phosphoprotein gene cluster at 4q13 to nuclear receptor subfamily 4 group a member 3 at 9q31. This upregulates the transcription factor nuclear receptor subfamily 4 group A member 3, which can be detected by immunohistochemistry. The purpose of this pilot study is to evaluate the performance of nuclear receptor subfamily 4 group A member 3 immunostaining on whole-slide acinic cell carcinoma tissue, in comparison with discovered on GIST-1 immunostaining.
MATERIAL AND METHODS: We retrieved 6 cases of acinic cell carcinoma (AciCC), including 5 conventional low-grade and 1 dedifferentiated high-grade. Immunohistochemistry (IHC) for nuclear receptor subfamily 4 group A member 3 (NR4A3) and discovered on GIST-1 (DOG1) were performed at the University of Pittsburgh Medical Centre in Pittsburgh, Pennsylvania on all retrieved cases.
RESULTS: The result shows that NR4A3 IHC shows better performance than DOG1 IHC: 5 of the 6 (83.3%) AciCC cases (including the dedifferentiated high-grade) demonstrated strong diffuse nuclear staining for NR4A3, also five AciCC cases (including the dedifferentiated high-grade) demonstrated weak to moderate membranous staining with variable distribution for DOG1. Moreover, only 3 (50%) cases showed complete membranous staining with DOG1.
CONCLUSIONS: This pilot study showed that nuclear receptor subfamily 4 group A member 3 immunostaining is a sensitive marker for acinic cell carcinoma and of better utility than discovered on GIST-1 immunostaining in making a diagnosis of acinic cell carcinoma.
Copyright © Owosho A, Tyler D, Adesina O, Odujoko O, Summersgill K. Published in the JOURNAL OF ORAL & MAXILLOFACIAL RESEARCH (http://www.ejomr.org), 31 March 2021.

Entities:  

Keywords:  gene rearrangement; immunohistocytochemistry; malignant neoplasms

Year:  2021        PMID: 33959239      PMCID: PMC8085676          DOI: 10.5037/jomr.2021.12104

Source DB:  PubMed          Journal:  J Oral Maxillofac Res        ISSN: 2029-283X


INTRODUCTION

Acinic cell carcinoma (AciCC) of salivary gland is a rare tumour accounting for approximately 10% of primary salivary gland malignancies [1]. It is most commonly located in the parotid gland and occurs more commonly in females [2]. AciCC originates from the acinar epithelium, showing serous differentiation resembling normal acini of salivary glands. AciCC usually presents as a low-grade malignancy with favourable prognosis; a small proportion of them could be associated with dedifferentiated high-grade transformation with poorer prognosis [3,4]. Until recently, the diagnosis of AciCC was solely based on its acinar differentiation aided by demonstrating cytoplasmic PAS-positive zymogen granules and non-specific membranous/cytoplasmic immunohistochemical expression of discovered on GIST-1 (DOG1), a marker of acinar and intercalated duct differentiation [3,5,6]. In 2019, whole-genome sequencing of AciCC of salivary gland identified a recurrent and specific [t(4;9)(q13;q31)] genomic rearrangement [7]. This rearrangement results in the translocation of the active enhancer regions from the secretory calcium-binding phosphoprotein (SCPP) gene cluster at 4q13 to the transcription start site of transcription factor nuclear receptor subfamily 4 group A member 3 (NR4A3) at 9q31, leading to the up-regulation of NR4A3 [7]. The overexpression of the NR4A3 protein can be detected by immunohistochemistry (IHC) and has been shown to be more sensitive for AciCC than NR4A3 FISH by being present in AciCC that are negative for SCPP-NR4A3 translocation [8]. A minor subset (< 5%) of AciCC harbours the HTN3-MSANTD3 translocation [9,10]. Interestingly, this subset of AciCC expresses NR4A3 by IHC [8,11]. NR4A3 expression has not been reported in any other salivary gland neoplasm [8,11,12]. The aim of this observatory pilot study is to evaluate the performance of nuclear receptor subfamily 4 group A member 3 immunostaining on whole-slide (conventional low-grade and dedifferentiated high-grade) acinic cell carcinoma tissue and in comparison to discovered on GIST-1 immunostaining.

MATERIAL AND METHODS

The study was approved by the Ethics and Research Committee of Obafemi Awolowo University Teaching Hospitals Complex, Obafemi Awolowo University, Ile-Ife, Nigeria (Protocol No: ERC/2019/06/06) and exempt from review by the Institutional Review Board of A.T. Still University, Kirksville, United States, for not being a human subject study. Cases of acinic cell carcinomas were retrieved from Joint Base San Antonio-Lackland Air Force Base (Brooke Army Medical Centre and Wilford Hall Ambulatory Surgical Centre), Texas and Department of Morbid Anatomy and Forensic Medicine, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria August 2020 to September 2020. IHC for NR4A3 and DOG1 were performed at the University of Pittsburgh Medical Centre in Pittsburgh, Pennsylvania on all retrieved cases from August 2020 to September 2020. IHC for DOG1 (1 : 50 dilution; RM-9132-5 [1.1] - Thermo Fisher Scientific; Waltham, Massachusetts, United States) was performed using an automated IHC system (Ventana BenchMark® ULTRA - Roche Diagnostics; Basel, Switzerland) on 4-μm-thick sections of formalin-fixed paraffin-embedded (FFPE) tissue. DOG1 staining was classified based on its distribution as membranous (apical or complete) and/or cytoplasmic. IHC for NR4A3 (NOR-1) (1 : 50 dilution; SC-393902 [H-7] - Santa Cruz Biotechnology, Inc.; Dallas, Texas, United States) was performed using an automated IHC system (Leica Bond-III - Leica Biosystems; Wetzlar, Germany) on 4-μm-thick sections of FFPE tissue. Only nuclear staining was considered positive in the interpretation of NR4A3 IHC. Distribution of staining was scored as: 0 (no staining), 1+ (1 to 33%), 2+ (34 to 66%), and 3+ (67 to 100%) and intensity (weak, moderate or strong) for both NR4A3 and DOG1. Staining of any intensity in at least 1% of neoplastic cells was considered positive, as previously described [11].

RESULTS

Clinicopathologic characteristics of cohort A total of 6 AciCC of salivary gland cases were retrieved. Patient demographics are presented in Table 1. All patients were females with ages ranging from 30 to 83 years old (median, 50 years). All tumours were located in the parotid gland. The size of the tumours ranged from 2 to 4.4 cm. Five cases are conventional low-grade and 1 case showed dedifferentiated high-grade transformation areas.
Table 1

Clinicopathologic features of acinic cell carcinomas

Case no. Age (years) Gender Location Size (cm) Diagnosis
Case 1 45 Female Parotid 2.1 Conventional

Case 2 83 Female Parotid 4.4 Dedifferentiated

Case 3 37 Female Parotid 2 Conventional

Case 4 74 Female Parotid 3 Conventional

Case 5 55 Female Parotid 2 Conventional

Case 6 30 Female Parotid 4 Conventional
Clinicopathologic features of acinic cell carcinomas Immunohistocytochemistry Results of NR4A3 and DOG1 IHCs are summarized in Table 2. For NR4A3, 5 (83.3%) AciCC cases (cases 1 to 5) demonstrated strong nuclear reactivity in 67 - 100% of neoplastic cells (3+) (Figures 1, 2 and 3). One case (case 6) showed no nuclear reactivity in any neoplastic cells (0). Acinar cells in normal salivary gland tissue in all cases showed no reactivity to NR4A3. For DOG1, 5 (83.3%) AciCC cases (cases 1 - 4, 6) demonstrated any reactivity in neoplastic cells (at least weak intensity of at least 1+ distribution) (Figures 1 and 2).
Table 2

Summary of NR4A3 and DOG1 immunohistochemistry result

Case no. NR4A3 IHC DOG1 IHC


Interpretation Intensity Distribution Any staining Apical membranous staining Complete membranous staining

Interpretation Intensity Distribution
Case 1 Positive Strong 3+ Positive - Positive Weak-moderate 3+

Case 2 Positive Strong 3+ Positive - Positive Weak-moderate 3+

Case 3 Positive Strong 3+ Positive Yes Negative NA NA

Case 4 Positive Strong 3+ Positive - Positive Weak-moderate 3+

Case 5 Positive Strong 3+ Negative - Negative NA NA

Case 6 Negative NA 0 Positive Yes Negative NA NA

NA = not applicable, IHC = immunohistochemistry.

Figure 1

Histopathology of case 1, conventional acinic cell carcinoma of the parotid gland in a 45-year old female.

A = morphology shows a solid lobulated growth pattern separated by fibrous septa with prominent basophilic zymogen granules (haematoxylin and eosin, original magnification x100).

B = strong diffuse nuclear staining with NR4A3 IHC (original magnification x100).

C = weak to moderate diffuse complete membranous staining with DOG1 IHC (original magnification x100).

Figure 2

Histopathology of case 2, dedifferentiated high-grade acinic cell carcinoma of the parotid gland in an 83-year old female.

A = morphology shows tumour nest with areas of central comedo necrosis (haematoxylin and eosin, original magnification x100).

B = strong diffuse nuclear staining with NR4A3 IHC (original magnification x100).

C = weak to moderate diffuse complete membranous staining with DOG1 IHC (original magnification x100).

Figure 3

Histopathology of case 5, conventional acinic cell carcinoma of the parotid gland in a 55-year old female.

A = strong diffuse nuclear staining with NR4A3 IHC (original magnification x200).

B = no staining with DOG1 IHC (original magnification x200).

Histopathology of case 1, conventional acinic cell carcinoma of the parotid gland in a 45-year old female. A = morphology shows a solid lobulated growth pattern separated by fibrous septa with prominent basophilic zymogen granules (haematoxylin and eosin, original magnification x100). B = strong diffuse nuclear staining with NR4A3 IHC (original magnification x100). C = weak to moderate diffuse complete membranous staining with DOG1 IHC (original magnification x100). Histopathology of case 2, dedifferentiated high-grade acinic cell carcinoma of the parotid gland in an 83-year old female. A = morphology shows tumour nest with areas of central comedo necrosis (haematoxylin and eosin, original magnification x100). B = strong diffuse nuclear staining with NR4A3 IHC (original magnification x100). C = weak to moderate diffuse complete membranous staining with DOG1 IHC (original magnification x100). Histopathology of case 5, conventional acinic cell carcinoma of the parotid gland in a 55-year old female. A = strong diffuse nuclear staining with NR4A3 IHC (original magnification x200). B = no staining with DOG1 IHC (original magnification x200). Summary of NR4A3 and DOG1 immunohistochemistry result NA = not applicable, IHC = immunohistochemistry. Three of the 5 cases (cases 1, 2 and 4) demonstrated weak to moderate complete membranous and some cytoplasmic staining in 67 - 100% distribution (3+) (Figures 1 and 2). Case 5 showed no reactivity (0) and cases 3 and 6 only demonstrated weak apical membranous staining (1+). Acinar cells in normal salivary gland tissue in all cases showed canalicular pattern of staining to DOG1.

DISCUSSION

AciCC of salivary gland is characterized by recurrent and specific chromosomal rearrangement [t(4;9)(q13;q31)], resulting in the translocation of SCPP gene cluster at 4q13 to NR4A3 at 9q31 [7]. This upregulates the transcription factor NR4A3, which can be detected by IHC. NR4A3 (NOR-1) IHC has been evaluated in 94 cases of AciCC and in 157 non-AciCC salivary gland tumours (including secretory carcinoma, mucoepidermoid carcinoma, adenoid cystic carcinoma, salivary duct carcinoma, basal cell adenocarcinoma, myoepithelial carcinoma, epithelial-myoepithelial carcinoma, clear cell carcinoma, carcinoma ex-pleomorphic adenoma, adenocarcinoma NOS, pleomorphic adenoma, Warthin tumour, oncocytoma, and myoepithelioma) by 4 recent studies, reporting a 97.9% sensitivity and 100% specificity as a nuclear marker for AciCC [8,11-13]. NR4A3 by FISH in AciCC is 100% specific; however, its sensitivity has been reported to be lower (53/69, 76.8%) [8,11]. In this study, 5 out of 6 AciCC cases were positive for NR4A3 IHC. Several salivary gland tumours are characterized by recurrent chromosomal rearrangements, such as PLAG1 rearrangements in pleomorphic adenoma [14], PRKD1 rearrangements in cribriform adenocarcinoma/polymorphous adenocarcinoma [15], EWSR1 rearrangement in hyalinising clear cell carcinoma [16], MYB/MYBL1-NFIB in adenoid cystic carcinoma [17], CRTC1/CRTC3-MAML2 in mucoepidermoid carcinoma [18], NCOA4/TRIM27-RET in intraductal carcinoma of salivary glands [19], MEF2C-SS18 in microsecretory adenocarcinoma [20], and ETV6 rearrangements in secretory carcinoma of salivary glands [21]. Similar to NR4A3, transcription factors PLAG1 and MYB are upregulated in pleomorphic adenoma and adenoid cystic carcinoma, respectively. However, PLAG1 and MYB IHC are not specific to pleomorphic adenoma and adenoid cystic carcinoma [22,23], unlike NR4A3 IHC, which appears to be specific for AciCC in salivary tumours. NR4A3 rearrangement was initially described in extraskeletal myxoid chondrosarcoma with various gene partners such as EWSR1, FUS, TAF15, TCF12, HSPA8, and TFG. However, NR4A3 IHC lacks sensitivity for the diagnosis of extraskeletal myxoid chondrosarcoma [13]. AciCCs that are negative for NR4A3 IHC or NR4A3 by FISH may be because of alternative genomic rearrangement involving the other two subfamilies of NR4A nuclear receptors; NR4A1 (Nur77) and NR4A2 (Nurr1) [24]. One case of AciCC in Haller et al. [24], that was negative for NR4A3 IHC was found to be positive for NR4A2 (Nurr1) IHC, suggesting that NR4A2 could be an alternative oncogenic driver in rare cases of AciCCs that lack NR4A3 rearrangement. In our study, one case was negative for NR4A3 IHC could be positive for NR4A2 IHC, but it was not tersted.

CONCLUSIONS

Despite the limitations of this pilot study a comparison of nuclear receptor subfamily 4 group A member 3 and discovered on GIST-1 immunostaining in acinic cell carcinomas demonstrated that nuclear receptor subfamily 4 group A member 3 immunostaining shows better performance than discovered on GIST-1 immunostaining. All positive nuclear receptor subfamily 4 group A member 3 staining acinic cell carcinomas in this study demonstrated a strong intensity, with 3+ staining distribution, while discovered on GIST-1 staining demonstrated weak to moderate apical/complete membranous and cytoplasmic staining with variable distribution. Non-neoplastic salivary gland tissue showed no reactivity at all to nuclear receptor subfamily 4 group A member 3 immunostaining, while discovered on GIST-1 staining was present in non-neoplastic salivary gland tissue. The nuclear staining of nuclear receptor subfamily 4 group A member 3 immunostaining was easier to interpret compared to the membranous staining of discovered on GIST-1 immunostaining. In conclusion, the presented study showed that nuclear receptor subfamily 4 group A member 3 immunostaining is a sensitive marker for salivary gland acinic cell carcinoma and of better utility than discovered on GIST-1 immunostaining in making a diagnosis of salivary gland acinic cell carcinoma.
  24 in total

1.  Salivary gland carcinoma in Denmark 1990-2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA).

Authors:  Kristine Bjørndal; Annelise Krogdahl; Marianne Hamilton Therkildsen; Jens Overgaard; Jørgen Johansen; Claus A Kristensen; Preben Homøe; Christian Hjort Sørensen; Elo Andersen; Troels Bundgaard; Hanne Primdahl; Karin Lambertsen; Lisbeth Juhler Andersen; Christian Godballe
Journal:  Oral Oncol       Date:  2011-05-25       Impact factor: 5.337

2.  DOG1: a novel marker of salivary acinar and intercalated duct differentiation.

Authors:  Jacinthe Chênevert; Umamaheswar Duvvuri; Simion Chiosea; Sanja Dacic; Kathleen Cieply; Jean Kim; Daniel Shiwarski; Raja R Seethala
Journal:  Mod Pathol       Date:  2012-03-30       Impact factor: 7.842

3.  Microsecretory Adenocarcinoma: A Novel Salivary Gland Tumor Characterized by a Recurrent MEF2C-SS18 Fusion.

Authors:  Justin A Bishop; Ilan Weinreb; David Swanson; William H Westra; Hina S Qureshi; James Sciubba; Christina MacMillan; Lisa M Rooper; Brendan C Dickson
Journal:  Am J Surg Pathol       Date:  2019-08       Impact factor: 6.394

4.  Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations.

Authors:  K Kas; M L Voz; E Röijer; A K Aström; E Meyen; G Stenman; W J Van de Ven
Journal:  Nat Genet       Date:  1997-02       Impact factor: 38.330

5.  Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity.

Authors:  Alena Skálová; Tomas Vanecek; Radek Sima; Jan Laco; Ilan Weinreb; Bayardo Perez-Ordonez; Ivo Starek; Marie Geierova; Roderrick H W Simpson; Fabricio Passador-Santos; Ales Ryska; Ilmo Leivo; Zdenek Kinkor; Michal Michal
Journal:  Am J Surg Pathol       Date:  2010-05       Impact factor: 6.394

6.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.

Authors:  Marta Persson; Ywonne Andrén; Joachim Mark; Hugo M Horlings; Fredrik Persson; Göran Stenman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

7.  Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin.

Authors:  Ilan Weinreb; Lei Zhang; Laxmi M S Tirunagari; Yun-Shao Sung; Chun-Liang Chen; Bayardo Perez-Ordonez; Blaise A Clarke; Alena Skalova; Simion I Chiosea; Raja R Seethala; Daryl Waggott; Paul C Boutros; Christine How; Fei-Fei Liu; Jonathan C Irish; David P Goldstein; Ralph Gilbert; Nasir Ud Din; Adel Assaad; Jason L Hornick; Lester D R Thompson; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2014-06-18       Impact factor: 5.006

8.  Clinicopathologic and Immunophenotypic Characterization of 25 Cases of Acinic Cell Carcinoma with High-Grade Transformation.

Authors:  Lester D Thompson; Muhammad N Aslam; Jennifer N Stall; Aaron M Udager; Simion Chiosea; Jonathan B McHugh
Journal:  Head Neck Pathol       Date:  2015-08-06

9.  Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions: A Report of 17 cases.

Authors:  Alena Skálová; Tomas Vanecek; Emmanuelle Uro-Coste; Justin A Bishop; Ilan Weinreb; Lester D R Thompson; Stefano de Sanctis; Marco Schiavo-Lena; Jan Laco; Cécile Badoual; Thalita Santana Conceiçao; Nikola Ptáková; Martina Baněčkova; Marketa Miesbauerová; Michal Michal
Journal:  Am J Surg Pathol       Date:  2018-11       Impact factor: 6.394

10.  Characterisation of DOG-1 Expression in Salivary Gland Tumours and Comparison with Myoepithelial Markers.

Authors:  Syed A Khurram; Paul M Speight
Journal:  Head Neck Pathol       Date:  2018-04-18
View more
  3 in total

1.  MAML2-Rearranged Mucoepidermoid Carcinoma of the Parotid Gland: A Report in a 20-Month-Old Toddler.

Authors:  Adepitan A Owosho; Abiodun S Olatunji; Adewale F Adejobi; Olawumi A Fatusi; Toluwaniyin Okunade; Kelly Maddux; Justin Shaw; Kurt F Summersgill
Journal:  Case Rep Dent       Date:  2022-03-29

Review 2.  Comprehensive insights into the function and molecular and pharmacological regulation of neuron-derived orphan receptor 1, an orphan receptor.

Authors:  Hongxiang Hong; Jianbin Su; Chao Huang; Xu Lu; Zhiming Cui
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

Review 3.  DOG1 as an Immunohistochemical Marker of Acinic Cell Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Vincenzo Fiorentino; Patrizia Straccia; Pietro Tralongo; Teresa Musarra; Francesco Pierconti; Maurizio Martini; Guido Fadda; Esther Diana Rossi; Luigi Maria Larocca
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.